Home

John P. Schmid

CIK 1478916 · Chief Financial Officer · last filed 2026-06-17

John P. Schmid is a Chief Financial Officer who has filed 83 SEC Form 4 insider transactions across 9 companies since 2010. The most recent filing, for TRAX, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.36M

Companies

9

Total Filings

83

Lifetime Open-Market Net

-$1.09M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ANAB Director 37,652 $52.11 $1.96M -$1.16M 18 2026-06-17
TRAX Director 37,652 $41.85 $1.58M $0 4 2026-06-17
DSGN Director 57,639 $11.87 $684.2K $99.7K 7 2026-06-11
BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted 30,000 $9.90 $297.0K $0 1 2025-08-11
Poseida Therapeutics, Inc. (PSTX) Delisted Director 0 $9.50 $0 $0 7 2025-01-08
XERS Director 138,359 $8.24 $1.14M $50.1K 12 2024-08-13
Neos Therapeutics, Inc. (NEOS) Delisted Director 0 $1.15 $0 $0 6 2021-03-19
Auspex Pharmaceuticals, Inc. (ASPX) Delisted Chief Financial Officer 0 — — $0 2 2015-05-06
Trius Therapeutics Inc (TSRX) Delisted Chief Financial Officer 107,639 — — -$85.0K 23 2013-03-11

Recent Filings

83 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 TRAX Exer (M) +6,030 $0 EDGAR
2026-06-17 ANAB Exer (M) +6,030 $0 EDGAR
2026-06-12 TRAX Grant (A) — $0 EDGAR
2026-06-11 DSGN Grant (A) — $0 EDGAR
2026-05-14 TRAX Grant (A) — $0 EDGAR
2026-04-22 ANAB Mixed — $0 EDGAR
2026-04-22 TRAX Grant (A) — $0 EDGAR
2026-04-01 ANAB Sell (S) −20,645 -$1.16M EDGAR
2026-03-30 ANAB Notice (144) −20,645 -$1.16M EDGAR
2026-01-08 ANAB Grant (A) — $0 EDGAR
Showing 1–10 of 83
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.